Review: PD1/PDL1 spatial interactions predict pembrolizumab response in metastatic urothelial carcinoma

This review summarizes a proof-of-concept study that analyzed PD1/PDL1 spatial interactions in tumor samples from patients with metastatic urothelial carcinoma receiving pembrolizumab. The study found that PD1/PDL1 interactions involving cytotoxic CD8CD3 T cells were significantly enriched in complete responders and rare in patients with progressive disease. Moreover, these spatial interactions provided superior discrimination of clinical response compared to single marker PD-L1 expression or immune cell abundance alone.

The review highlights that this approach establishes a generalizable framework for translating spatial signaling biology into predictive tools for immunotherapy response across tumor types. However, the authors note important limitations: the analysis was a proof of concept applied to tumor samples, and specific statistical values such as effect sizes, p-values, and confidence intervals were not reported. Therefore, the findings should be interpreted as preliminary associations rather than definitive predictors.

No safety data or adverse events were reported in the reviewed study. The practice relevance is currently limited to hypothesis generation, as the framework requires validation in larger, prospective cohorts before clinical application. Clinicians should recognize that while spatial immune profiling holds promise, it is not yet ready for routine use in guiding pembrolizumab therapy for metastatic urothelial carcinoma.